- Shilpa Medicare has received US Food and Drug Administration (USFDA) approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg.
- Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD), gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA.
- As per IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets is approximately USD 885 million.
No comments:
Post a Comment